Saturday, October 31, 2026

Redfin Stock Went Down By Over 34% In The Last 21 Sessions

ViaNews Editorial Team

August 10, 2023

Redfin Stock Went Down By Over 34% In The Last 21 Sessions

Redfin Corp (NASDAQ: RDFN), a respected residential real estate brokerage firm, is presently observing a distressing decline in stock value. In the span of just 21 sessions, its shares have plummeted by 34.83% - going from $0.59 on July 12th 2023 down to $0.16 as of 14:44 EST on the following Thursday afternoon.

Contrasting Performance

While NASDAQ reported a modest gain of 0.05%, Redfin's previous close was significantly below this at $0.23, and it was an alarming 42.14% below its 52-week high of $0.68. On the other hand, Seattle-based RealEstateMarket, an online real estate marketplace that also offers additional services such as property sales assistance and mortgage origination, etc., has been performing steadily.

Concerns over Profitability

Redfin's profitability might instigate investor concern. Although its trailing 12-month earnings per share (EPS) stood at $2.89, Redfin's return on equity (ROE) - a metric suggesting efficiency in generating profits relative to shareholder equity - was significantly in the negative at -173.25% over this period.

Declining Sales Projections

Unfortunately, Redfin's sales projection seems to affirm these undesirable profitability metrics. The firm predicts a severe decrease in sales - an estimated 54.6% decline is expected for this quarter, with a 52% decrease foreseen for the following quarters.

Overall Market Outlook

As it stands, Redfin's shares are currently trading at $0.16, far below the 52-week high of $0.68 but considerably above its low point of $0.08. Those participating in the market should monitor Redfin's financial performance in addition to wider trends in the housing market to get a thorough understanding of potential impacts on its valuation.

More news about Redfin (RDFN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com